Latest & greatest articles for dabigatran

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dabigatran or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dabigatran and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dabigatran

22. Dabigatran (Pradaxa) in deep vein thrombosis and pulmonary embolism

Dabigatran (Pradaxa) in deep vein thrombosis and pulmonary embolism Prescrire IN ENGLISH - Spotlight ''In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism'', 1 June 2015 {1} {1} {1} | | > > > In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |  (...)  |   |   |   |   |  Spotlight In the June issue of Prescrire International: Dabigatran (Pradaxa°) in deep vein thrombosis and pulmonary embolism FREE DOWNLOAD In the New Products section of the June issue: compared with adjusted-dose warfarin, dabigatran provides no tangible advantages for patients with pulmonary embolism or deep vein thrombosis. Warfarin remains the standard drug. Full text available for free download. Summary The anticoagulant dabigatran

Prescrire2015

24. Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran ? first line

Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran ? first line Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran – first line Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran – first line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSC. Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran – first line . Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2015 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Anticoagulants; Benzimidazoless; Blood Coagulation; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Thromboembolism Language Published English Country of organisation England English

Health Technology Assessment (HTA) Database.2015

26. Cohort study: Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin

Cohort study: Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin | Evidence (...) patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin Article Text Aetiology/Harm Cohort study Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin John W Eikelboom , Jackie

Evidence-Based Medicine (Requires free registration)2015

27. Praxbind (idarucizumab) - For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa?s blood-thinning effects

Praxbind (idarucizumab) - For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa?s blood-thinning effects Praxbind (idarucizumab) U.S. Department of Health and Human Services Search FDA Submit search Praxbind (idarucizumab) Vraylar (Cariprazine) Company: Boehringer Ingelheim Pharmaceuticals Application No.: 761025 Orig1 Approval Date: October 16, 2015 Persons with disabilities having problems accessing

FDA - Drug Approval Package2015

28. Bleeding events with dabigatran or warfarin in patients with venous thromboembolism

Bleeding events with dabigatran or warfarin in patients with venous thromboembolism 26403199 2016 01 28 2016 12 20 2016 12 30 0340-6245 115 2 2016 Jan Thrombosis and haemostasis Thromb. Haemost. Bleeding events with dabigatran or warfarin in patients with venous thromboembolism. 291-8 10.1160/TH15-04-0319 Dabigatran was as effective as warfarin for the acute treatment of venous thromboembolism in the RE-COVER and RE-COVER II trials. We compared the incidence of bleeding with dabigatran versus (...) warfarin in pooled data from these studies. The localisation, bleeding severity, and the impact of key factors on the incidence of bleeding, were compared between the dabigatran and warfarin treatment group. Altogether, 2553 patients received dabigatran and 2554 warfarin, each for a mean of 164 days. The incidence of any bleeding event was significantly lower with dabigatran (hazard ratio [HR] 0.70; 95% confidence interval [CI], 0.61-0.79), as was the incidence of the composite of MBEs and clinically

EvidenceUpdates2015

30. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis

Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis Providencia R, Albenque JP, Combes S (...) , Bouzeman A, Casteigt B, Combes N, Narayanan K, Marijon E, Boveda S CRD summary This review indicated that dabigatran for catheter ablation in patients with atrial fibrillation had a similar incidence of thromboembolic events and major bleeding to that of warfarin, with low event rates overall. The observational nature of nearly all the studies in the review, coupled with the few events, mean that the authors' conclusions should not be seen as definitive. Authors' objectives To compare the efficacy

DARE.2014

31. Dabigatran (Pradaxa): life-threatening bleeding

Dabigatran (Pradaxa): life-threatening bleeding Prescrire IN ENGLISH - Spotlight: Archive ''Dabigatran (Pradaxa°): life-threatening bleeding'', 1 February 2013 {1} {1} {1} | | > > > Dabigatran (Pradaxa°): life-threatening bleeding Spotlight: Archives Every month, the subjects in Prescrire’s Spotlight. 2013 :  |   |  Spotlight Archives Dabigatran (Pradaxa°): life-threatening bleeding FEATURED REVIEW Dabigatran is an oral anticoagulant that inhibits thrombin but not vitamin K (...) . Pharmacovigilance studies have identified several situations in which patients have an increased risk of serious bleeding with dabigatran. Dabigatran should be reserved for patients at high risk of thrombosis in whom antivitamin K therapy poses difficult problems. Full review (3 pages) available for download by subscribers. Abstract Dabigatran (Pradaxa°) is an oral anticoagulant that inhibits thrombin but not vitamin K. In mid-2012, there was no commercial test to monitor its anticoagulant effect, nor

Prescrire2014

32. Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience

Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience Prescrire IN ENGLISH - Spotlight ''Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience '', 1 June 2013 {1} {1} {1} | | > > > Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight Bleeding with dabigatran, rivaroxaban, apixaban: no antidote, and little clinical experience FEATURED REVIEW Dabigatran, rivaroxaban and apixaban are oral anticoagulants used to prevent or treat thrombosis. Difficulties in the management of bleeding weigh heavily in the balance of potential harm versus potential benefit of these drugs. Full review (5 pages) available for download by subscribers. Abstract Dabigatran, rivaroxaban and apixaban

Prescrire2014

33. [Overview of dabigatran usage among people insured by the public prescription drug insurance plan]

[Overview of dabigatran usage among people insured by the public prescription drug insurance plan] Portrait de l'usage du dabigatran chez les personnes assurées par le régime public d'assurance médicaments [Overview of dabigatran usage among people insured by the public prescription drug insurance plan] Portrait de l'usage du dabigatran chez les personnes assurées par le régime public d'assurance médicaments [Overview of dabigatran usage among people insured by the public prescription drug (...) insurance plan] Tremblay E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Tremblay E. Portrait de l'usage du dabigatran chez les personnes assurées par le régime public d'assurance médicaments . [Overview of dabigatran usage among people insured by the public prescription drug insurance plan] . Quebec: Institut national d'excellence en sante et

Health Technology Assessment (HTA) Database.2014

34. Randomised controlled trial: Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapy

Randomised controlled trial: Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapy Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapy | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapy Article Text Therapeutics Randomised controlled trial Evidence suggests dabigatran is an effective and safe

Evidence-Based Medicine (Requires free registration)2014

35. Dabigatran versus warfarin in patients with mechanical heart valves.

Dabigatran versus warfarin in patients with mechanical heart valves. BACKGROUND: Dabigatran is an oral direct thrombin inhibitor that has been shown to be an effective alternative to warfarin in patients with atrial fibrillation. We evaluated the use of dabigatran in patients with mechanical heart valves. METHODS: In this phase 2 dose-validation study, we studied two populations of patients: those who had undergone aortic- or mitral-valve replacement within the past 7 days and those who had (...) undergone such replacement at least 3 months earlier. Patients were randomly assigned in a 2:1 ratio to receive either dabigatran or warfarin. The selection of the initial dabigatran dose (150, 220, or 300 mg twice daily) was based on kidney function. Doses were adjusted to obtain a trough plasma level of at least 50 ng per milliliter. The warfarin dose was adjusted to obtain an international normalized ratio of 2 to 3 or 2.5 to 3.5 on the basis of thromboembolic risk. The primary end point

NEJM2013

36. Dabigatran and Mechanical Heart Valves - Not as Easy as We Hoped.

Dabigatran and Mechanical Heart Valves - Not as Easy as We Hoped. Dabigatran and mechanical heart valves--not as easy as we hoped. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 23991659 Format MeSH and Other (...) Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2013 Sep 26;369(13):1264-6. doi: 10.1056/NEJMe1310399. Epub 2013 Aug 31. Dabigatran and mechanical heart valves--not as easy as we hoped. . Comment on [N Engl J Med. 2013] PMID: 23991659 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed

NEJM2013

38. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Harrington AR, Armstrong EP, Nolan PE, Malone DC Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) . Interventions The four interventions were warfarin, apixaban 5mg twice daily, dabigatran 150mg twice daily, and rivaroxaban 20mg once daily. Warfarin dose was assumed to be adjusted to achieve the patient's target international normalised ratio (INR). Location/setting USA/in-patient and out-patient care. Methods Analytical approach: A Markov model, with one-month cycles, combined the published data. The time horizon was 30 years and the authors stated that the perspective was societal. Effectiveness data

NHS Economic Evaluation Database.2013

39. Ischemic stroke in an obese patient receiving dabigatran.

Ischemic stroke in an obese patient receiving dabigatran. Ischemic stroke in an obese patient receiving dabigatran. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 23782198 Format MeSH and Other Data E-mail (...) Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2013 Jun 20;368(25):2440-2. doi: 10.1056/NEJMc1215900. Ischemic stroke in an obese patient receiving dabigatran. , , , . PMID: 23782198 DOI: [Indexed for MEDLINE] Free full text Publication types MeSH terms Substances Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full

NEJM2013

40. Dabigatran and Postmarketing Reports of Bleeding.

Dabigatran and Postmarketing Reports of Bleeding. Dabigatran and postmarketing reports of bleeding. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 23484796 Format MeSH and Other Data E-mail Subject Additional (...) text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2013 Apr 4;368(14):1272-4. doi: 10.1056/NEJMp1302834. Epub 2013 Mar 13. Dabigatran and postmarketing reports of bleeding. 1 , , . 1 Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA. PMID: 23484796 DOI: [Indexed for MEDLINE] Free full text MeSH terms Substances Full Text Sources Other

NEJM2013